An act relating to increasing the transparency of prescription drug costs and spending
H.202 is a prescription drug transparency bill that would change how certain drug costs are disclosed to consumers and regulators in Vermont. It would prohibit pharmacy benefit managers from requiring a covered person to pay more than the lowest of several amounts, including the plan cost-sharing amount, the maximum allowable cost, the cash price after discounts, or the National Average Drug Acquisition Cost plus a Medicaid-based dispensing fee. The bill also requires pharmacies to post notices telling customers they can ask staff to disclose these pricing comparisons.
The bill further expands reporting and disclosure requirements around the federal 340B drug pricing program. Hospitals participating in 340B would have to file annual reports with the Green Mountain Care Board detailing acquisition costs, payments received, vendor relationships, claim counts, administrative expenses, and how 340B savings benefit the community. Health insurers would have to send each covered person an annual statement showing the total amount spent on prescription drugs on that person’s behalf, net of rebates and discounts. Covered entities participating in 340B would also have to notify patients when prescribed drugs were purchased through the program, and hospitals would have to direct patients to the public 340B report.
The bill’s impact on state law would be to add new consumer disclosure rights, new limits on pharmacy benefit manager pricing practices, and new annual reporting obligations for hospitals, insurers, and other 340B-covered entities. It would amend existing insurance and health care statutes to create a more transparent framework for prescription drug pricing and spending, while giving the Green Mountain Care Board a new role in collecting and publishing hospital 340B data. Affected parties would include pharmacy benefit managers, pharmacies, health insurers, hospitals, contract pharmacies, and patients covered by health plans or receiving 340B-related prescriptions.
Overall sentiment appears supportive of the bill’s transparency goals, based on its framing as an act to increase disclosure of prescription drug costs and spending. The bill text emphasizes consumer access to price information and public accountability for 340B participation, suggesting a policy direction aimed at helping patients understand what drugs cost and how savings are used. No committee transcripts or votes were provided, so there is no recorded debate or formal vote history to indicate broader legislative support or opposition.
The main points of contention likely center on the administrative burden and financial disclosure requirements imposed on hospitals and insurers, as well as the limits placed on pharmacy benefit managers. Hospitals may view the 340B reporting mandate as extensive and potentially sensitive because it requires disclosure of vendor contracts, expenses, and claim-level summaries by payer type. Pharmacy benefit managers and insurers could object to the pricing floor and reporting obligations, while supporters would likely argue that the bill improves consumer protection, price transparency, and oversight of drug spending.
The bill would amend Vermont law to impose new prescription drug pricing limits on pharmacy benefit managers, require pharmacies to post consumer notices about available price comparisons, create annual hospital reporting obligations for 340B participation, and require insurers and 340B-covered entities to provide annual spending and purchase disclosures to patients. It would affect the practices of PBMs, pharmacies, hospitals, insurers, contract pharmacies, and other 340B participants, and would expand the Green Mountain Care Board’s oversight role by requiring publication of hospital 340B reports.
The bill appears to have a generally favorable policy orientation because it is framed around transparency, consumer information, and accountability in prescription drug pricing. The available materials do not include committee testimony or votes, so there is no direct evidence of partisan or stakeholder support and opposition. Based on the bill’s structure, supporters would likely include consumer advocates and transparency proponents, while affected industry groups may be more cautious or resistant.
Likely areas of contention include the new cap on what pharmacy benefit managers may require covered persons to pay, which could be viewed as interfering with PBM contracting and pricing arrangements. Hospitals may also object to the breadth of the 340B reporting requirements, especially the disclosure of acquisition costs, payments, vendor names, claim counts, and administrative expenses. Insurers and covered entities could raise concerns about the cost and complexity of generating individualized annual spending reports and patient notices, while supporters would argue these disclosures are necessary for transparency and consumer understanding.